A Study of the Effects of Ranolazine Using Automated Quantitative Analysis of Serial Myocardial Perfusion Images

JACC: Cardiovascular Imaging

Volumn 2, Issue 11, 2009, Pages 1301-1309

  Venkataraman, Rajesh ^a   Belardinelli, Luiz ^b   Blackburn, Brent ^b   Heo, Jaekyeong ^a   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

coronary artery disease; exercise testing; ischemia; myocardial perfusion imaging; ranolazine; single photon emission computed tomography

Indexed keywords

RANOLAZINE;

ADD ON THERAPY; ANGINA PECTORIS; ARTICLE; AUTOANALYSIS; BLOOD RHEOLOGY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DYSPNEA; ECG ABNORMALITY; FATIGUE; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEMODYNAMIC STRESS; HUMAN; HYPOTENSION; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT COURSE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX PAIN; TREADMILL EXERCISE;

ACETANILIDES; AGED; ANGINA PECTORIS; AUTOMATION, LABORATORY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PILOT PROJECTS; PIPERAZINES; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 70350776813     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2009.09.006     Document Type: Article

References (24)

1. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
2. Zoghbi G.J., Dorfman T.A., and Iskandrian A.E. The effects of medications on myocardial perfusion. J Am Coll Cardiol 52 (2008) 401-416
3. Belardinelli L., Shryock J.C., and Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 Suppl 4 (2006) iv6-iv14
4. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291 (2004) 309-316
5. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
6. Gaffney S.M. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy 26 (2006) 135-142
7. Hale S.L., Shryock J.C., Belardinelli L., Sweeney M., and Kloner R.A. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 44 (2008) 954-967
8. Koren M.J., Crager M.R., and Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol 49 (2007) 1027-1034
9. Stone P.H., Gratsiansky N.A., Blokhin A., Huang I.Z., and Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48 (2006) 566-575
10. Zaza A., Belardinelli L., and Shryock J.C. Pathophysiology and pharmacology of the cardiac "late sodium current". Pharmacol Ther 119 (2008) 326-339
11. Allely M.C., and Alps B.J. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 99 (1990) 5-6
12. Fraser H., Belardinelli L., Wang L., Light P.E., McVeigh J.J., and Clanachan A.S. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 41 (2006) 1031-1038
13. Hale S.L., Leeka J.A., and Kloner R.A. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther 318 (2006) 418-423
14. Zacharowski K., Blackburn B., and Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 418 (2001) 105-110
15. Iskandrian A.E., and Garcia E.V. Nuclear Cardiac Imaging: Principles and Applications. 4th edition (2008), Oxford University Press, Oxford
16. Mahmarian J.J., Iskandrian A.E., Cerqueira M.D., et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. J Am Coll Cardiol Img 2 (2009) 959-968
17. Murphy E., Cross H., and Steenbergen C. Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res 84 (1999) 1469-1470
18. Moss A.J., Zareba W., Schwarz K.Q., Rosero S., McNitt S., and Robinson J.L. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19 (2008) 1289-1293
19. Scirica B.M., Morrow D.A., Budaj A., et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome. Observations from the MERLIN-TIMI 36 (Metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-Thrombolysis in myocardial infarction 36) trial. J Am Coll Cardiol 53 (2009) 1411-1421
20. Wilson S.R., Scirica B.M., Braunwald E., et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized double-blind, placebo-controlled MERLIN-TIMI (Metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-Thrombolysis in myocardial infarction) 36 trial. J Am Coll Cardiol 53 (2009) 1510-1516
21. Morrow D.A., Scirica B.M., Chaitman B.R., et al., MERLIN-TIMI 36 investigators. Evaluation of the glycometabolic effects of ranolazine in patients with and diabetes mellitus in the MERLIN-TIMI 36 randomized control trial. Circulation 119 (2009) 2032-2039
22. Shaw L.J., Berman D.S., Maron D.J., et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 (2008) 1283-1291
23. Iskandrian A.E., Garcia E.V., and Faber T. Analysis of serial images: a challenge and an opportunity. J Nucl Cardiol 15 (2008) 23-26
24. Iskandrian A.E., Garcia E.V., Faber T., and Mahmarian J.J. Automated assessment of serial SPECT myocardial perfusion images. J Nucl Cardiol 16 (2009) 6-9